Skip to main content

The

Dow Jones Industrial Average

(

^DJI

) closed up 46 points (+0.4%) at 12,984. During the day, 614.5 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 818.6 million. The NYSE advances/declines ratio closed at 2,164 issues advancing vs. 843 declining with 104 unchanged.

The Dow component that led the way higher today was

Chevron

(NYSE:

CVX

), which sported an 85-cent gain (+0.8%) bringing the stock to $108.35. This single gain lifted the Dow Jones Industrial Average by 6.43 points or roughly accounting for 14% of the Dow's overall gain. Volume for Chevron ended the day at 5.5 million shares traded vs. an average daily trading volume of 8.8 million shares.

Chevron has a market cap of $212.53 billion and is part of the

basic materials

sector and

energy

industry. Shares are up 1% year to date as of Wednesday's close. The stock's dividend yield sits at 3%.

Chevron Corporation, through its subsidiaries, engages in petroleum, chemicals, mining, power generation, and energy operations worldwide. It operates in two segments, Upstream and Downstream. The company has a P/E ratio of 8.1, above the average energy industry P/E ratio of 7.9 and below the S&P 500 P/E ratio of 17.7.

TheStreet Recommends

TheStreet Ratings rates Chevron as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Holding the Dow back today was

Pfizer

(NYSE:

PFE

), which lagged the broader Dow index with a 33-cent decline (-1.5%) bringing the stock to $21.03. Volume for Pfizer ended the day at 38.8 million shares traded vs. an average daily trading volume of 43.5 million shares.

Pfizer has a market cap of $166.5 billion and is part of the

health care

sector and

drugs

industry. Shares are down 1.3% year to date as of Wednesday's close. The stock's dividend yield sits at 4.1%.

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company has a P/E ratio of 9.2, below the average drugs industry P/E ratio of 14.9 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a

buy

. Among the primary strengths of the company is its solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

null